Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 5, 2012, Pages 527-534

  Gallego Escuredo, José M ^a,b   Domingo, Pere ^c   Del Mar Gutiérrez, Maria ^c   Mateo, Maria G ^c   Cabeza, Maria C ^c,d   Fontanet, Angels ^c,d   Vidal, Francesc ^e   Domingo, Joan Carles ^a,b   Giralt, Marta ^a,b   Villarroya, Francesc ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Red de Investigación en SIDA RIS   (Spain)

^e HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Anti retroviral; Fibroblast growth factors; HIV 1; Lipodystrophy

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE; BETA KLOTHO PROTEIN, HUMAN; BETA-KLOTHO PROTEIN, HUMAN; FGF19 PROTEIN, HUMAN; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; MEMBRANE PROTEIN; MESSENGER RNA;

ADIPOSE TISSUE; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INSULIN RESISTANCE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL; BLOOD; CASE CONTROL STUDY; GENETICS; HIV ASSOCIATED LIPODYSTROPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED;

ADIPOSE TISSUE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA, MESSENGER;

EID: 84873142570     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318271c2c7     Document Type: Article

References (30)

1. Pullinger CR, Aouizerat BE, Gay C, et al Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus-infected adults. Metab Syndr Relat Disord. 2010;8:279-286.
2. Giralt M, Domingo P, Villarroya F. Adipose tissue biology and HIV-infection. Best Pract Res Clin Endocrinol Metab. 2011;25:487-499.
3. Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res. 2010;342:1-11.
4. Kharitonenkov A, Shiyanova TL, Koester A, et al FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627-1635.
5. Tomlinson E, Fu L, John L., et al Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology. 2002;143:1741-1747.
6. Bhatnagar S, Damron HA, Hillgartner FB Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem. 2009;284:10023-10033.
7. Wu X, Ge H, Lemon B., et al Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci U S A. 2009;106:14379-14384.
8. Kir S, Beddow SA, Samuel V.T., et al FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331:1621-1624.
9. Kurosu H, Choi M, Ogawa Y., et al Tissue-specific expression of betaKlo-tho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282:26687-26695.
10. Wu X, Li Y. Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis. Aging (Albany NY). 2009;1:1023-1027.
11. Domingo P, Gallego-Escuredo JM, Domingo J.C., et al Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS. 2010;24: 2629-2637.
12. Chen WW, Li L, Yang G.Y., et al Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008;116:65-68.
13. Zhang X, Yeung DC, Karpisek M, et al Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57:1246-1253.
14. Fisher FM, Chui PC, Antonellis P.J., et al Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59:2781-2789.
15. Lemieux S, Prud'homme D, Bouchard C, et al. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr. 1996;64:685-693.
16. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr. 2005;39:395-400.
17. Sugiuchi H, Uji Y, Okabe H., et al Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem. 1995;41:717-723.
18. Matthews DR, Hosker JP, Rudenski A.S., et al Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28: 412-419.
19. Gabrielsson BG, Johansson JM, Jennische E, et al Depot-specific expression of fibroblast growth factors in human adipose tissue. Obes Res. 2002;10:608-616.
20. Jones S. Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm. 2008;5:42-48.
21. Dushay J, Chui PC, Gopalakrishnan G.S., et al Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139:456-463.
22. Fon TK, Bookout AL, Ding X, et al Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol. 2010;24:2050-2064.
23. Moyers JS, Shiyanova TL, Mehrbod F, et al Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol. 2007;210:1-6.
24. Mráz M., Lacinová Z, Kaválková P, et al. Serum concentrations of fibro-blast growth factor 19 in patients with obesity and type 2 diabetes melli-tus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-a agonist treatment. Physiol Res. 2011;60:627-636.
25. Lundåsen T., Gälman C, Angelin B., et al Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med. 2006;260:530-536.
26. McRae M, Rezk NL, Bridges A.S., et al Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity. Pharma-cotherapy. 2010;30:17-24.
27. Nolan D, Hammond E, James I., et al Contribution of nucleoside-ana-logue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther. 2003;8:617-626.
28. Haubrich RH, Riddler SA, DiRienzo A.G., et al Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23:1109-1118.
29. Giralt M, Domingo P, Guallar J.P., et al HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-asso-ciated lipodystrophy. Antivir Ther. 2006;11:729-740.
30. Giralt M, Domingo P, Villarroya F. HIV-1 infection and the PPARgam-ma-dependent control of adipose tissue physiology. PPAR Res. 2009; 2009:607902.